Newsroom

JAMA Cardiol

Published Online: November 8, 2025

Today at the AHA congress in New Orleans, BridgeBio presented data showing that acoramidis significantly reduces all-cause mortality (through month 42) in people living with hereditary ATTR-CM population, with specific benefit noted in those living with the V122i variant. These data have also been published today in JAMA Cardiology.

You can read more information about this...

Be sure to catch up on the latest happenings in our fall newsletter here!

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
A three-way tussle has emerged in the growing ATTR amyloidosis market as Alnylam and BridgeBio Pharma have secured FDA approvals to challenge Pfizer.

Tafamidis, which Pfizer sells as Vyndaqel, Vyndamax and Vynmac, had the ATTR...

Below is a resource for our patients:

Taylor & Francis is a publisher of peer-reviewed medical journals. We publish a type of article called Plain Language Summary of Publications (PLSPs). These articles provide an overview of a published, scientific journal article written in non-technical language. These summaries enable a wide audience, including patient audiences, to be able to access and...

– ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM

– ACT-EARLY is a registrational, randomized, double blind, placebo controlled, event driven prevention study that...